Recently, our team attended CPHI 2025 in Frankfurt, an exceptional opportunity to experience the pulse of the global pharmaceutical industry and connect with key players shaping its future.
We were thrilled to participate in this year’s event, which once again served as a hub for innovation, collaboration, and new ideas.
Our colleagues Thomas, Robin, and Alen represented ISP at the fair, engaging with partners and experts across the pharma and biotech spectrum. Together, they explored cutting-edge developments in manufacturing, formulation, outsourcing, and commercialization, while reconnecting with clients, investors, and long-standing industry peers.
A particular highlight of our participation was our presentation on the current status of the pharmaceutical and biotech sectors through the lens of capital markets. In it, we shared insights into valuation trends, investor sentiment, and financing dynamics that continue to influence strategic decisions and M&A activity across the life sciences landscape. The strong interest from attendees underscored how closely market forces and industry innovation remain intertwined.
Our Manager Robin highlighted that this year’s CPHI was defined by a clear shift toward execution and resilience. Speed and adaptability now set the benchmark for leadership, practical implementation, rather than theoretical innovation, is what truly drives progress. He noted that the CDMO and contract services segment continues to show strong momentum, with the focus firmly on delivering pipeline projects efficiently and with agility. Digital transformation and data-driven operations have become standard expectations rather than differentiators, and topics such as supply-chain resilience, regional manufacturing, and risk management are now more than ever front of mind across the industry.
The energy at CPHI is always inspiring, and 2025 was no exception. From insightful presentations to spontaneous conversations on the exhibition floor, it was a fantastic opportunity to learn, exchange, and connect.
We’re already looking forward to CPHI 2026, where we’ll once again proudly represent ISP and continue advancing innovation and collaboration in pharma.